Skip to content

Paraneoplastic Syndrome in Hepatocellular Carcinoma Patients

Paraneoplastic Syndrome in Hepatocellular Carcinoma Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05846035
Enrollment
80
Registered
2023-05-06
Start date
2023-04-15
Completion date
2024-04-30
Last updated
2023-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma Patients

Brief summary

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world with rising incidence. Globally, there has been substantial variation in prevalence of risk factors for HCC over years, like control of viral hepatitis in developing countries but growing epidemic of fatty liver disease in developed world. Changing epidemiology of HCC is related to trends in these risk factors, Paraneoplastic syndromes (PNS) are defined as systemic, metabolic, or other distant consequences of malignancy resulting, either directly or indirectly, from production by the neoplasm of substances that gain access to the blood stream, thereby exerting their effects on distant organs or tissues There is four major HCC-associated paraneoplastic syndromes among Cirrhotic patients,i.e.hypercholesterolemia,hypoglycemia,hypercalcemia,and erythrocytosis .

Interventions

DIAGNOSTIC_TESTTriphasic C.T abdomen and pelvis

for cirrhotic patients to ensure hepatocellular carcinoma

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
40 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* \- Cirrhotic Patients with HCC. * HCC will be diagnosed based on Alpha -feto protein (AFP) and dynamic imaging.

Exclusion criteria

* \- Patient known to have primary parathyroid disease, patients with bone metastasis or excessive use of antacids. * Patients with secondary polycythemia (as chronic hypoxia) and patients with polycythemia rubra vera. * Patients with acute infections or GIT bleeding. * Patients with preexisting dyslipidemia. * Patients with significant cholestasis.

Design outcomes

Primary

MeasureTime frameDescription
the prevalence of Paraneoplastic Syndrome in cirrhotic Patients with HCC.12 monthsTo investigate the prevalence of PNS (hypoglycemia, hypercholesterolemia, hypercalcemia, erythrocytosis, and thrombocytosis) and clinical characteristics in cirrhotic Patients with HCC.

Countries

Egypt

Contacts

Primary ContactHala M Abdelhafeez, Resident
halamaher@med.sohag.edu.eg01027319657
Backup ContactAmr M Zaghloul, Assistant professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026